جستجوی استاد راهنمای دانشگاهی

Dr. Giulia Biancon is an Assistant Professor Adjunct in the Department of Medical Oncology and Hematology at Yale School of Medicine. She holds a PhD from the University of Milan (2019) and is a member of the Halene Lab, focusing on RNA biology and hematologic malignancies. Her research combines high-throughput methodologies to study RNA mechanisms in diseases like myeloid leukemias and splicing factor mutations. Education: PhD in Molecular Biology from the University of Milan (2019). Research Interests: RNA splicing, stress granules in cancer, epitranscriptomics, clonal hematopoiesis, and the interplay between genetic mutations and cellular pathways in blood cancers. Awards: 2024 Eclipse Award, 2022 ASH Abstract Achievement Award, and 2022 RNA Society Best Poster Award. Her work has been published in journals like Cell Reports , Blood , and Molecular Cell . Labs/Teams: Principal member of the Halene Lab and coordinator at the Yale Center for RNA Science and Medicine. Collaborates with institutions like the SeroNet network for immunology studies.

• RNA Biology
• Myeloid Malignancies
• Hematology
• +۴ مورد دیگر

Ross L. Levine, MD, is a distinguished Professor and Physician-Scientist at Memorial Sloan Kettering Cancer Center (MSKCC), holding the Edward P. Evans Endowed Chair for Myelodysplastic Syndromes (MDS). As Senior Vice President of Memorial Hospital’s Translational Research division, he leads groundbreaking work in hematologic malignancies, particularly leukemia and myeloproliferative neoplasms (MPNs). His research integrates clinical care with genomic and molecular studies to develop targeted therapies. Levine received his MD from Johns Hopkins University School of Medicine, followed by residency in Internal Medicine at Massachusetts General Hospital and fellowship in Hematology/Oncology at Dana-Farber Cancer Institute. Education: MD, Johns Hopkins University School of Medicine Residencies: Internal Medicine, Massachusetts General Hospital Fellowships: Hematology/Medical Oncology, Dana-Farber Cancer Institute Levine’s research focuses on the genetic and epigenetic drivers of myeloid cancers, including JAK-STAT pathway mutations in MPNs and AML. His team explores therapeutic strategies targeting CXCL8/CXCR2 signaling and clonal hematopoiesis. Key contributions include identifying JAK2 mutations in MPNs and advancing single-cell mutation analysis for clonal evolution studies. His clinical expertise includes treating patients with acute myeloid leukemia (AML), polycythemia vera, and myelofibrosis, performing bone marrow biopsies, and leading clinical trials for targeted therapies. Levine has pioneered translational research programs linking lab discoveries to patient care, emphasizing precision medicine. Awards & Honors: Pershing Square Sohn Prize (2014), Howard Hughes Medical Institute Early Career Award (2007), and multiple Leukemia & Lymphoma Society accolades. He holds leadership roles in professional societies, including co-chairing the American Society of Hematology’s 2016 Scientific Program. Levine’s lab, part of the Human Oncology & Pathogenesis Program (HOPP), collaborates with institutions globally. His work has been published in high-impact journals like Cancer Cell , Nature , and Blood , advancing understanding of cancer genetics and therapeutic innovation.

• Hematology
• Oncology
• Genetics
• +۴ مورد دیگر

Dr. Aaron Logan is a Clinical Associate Professor of Medicine at the University of California, San Francisco (UCSF). He specializes in the clinical management of acute leukemias, myelodysplastic syndromes, aplastic anemia, and hemophagocytic lymphohistiocytosis. Additionally, he directs a research laboratory focused on immune repertoire profiling following hematopoietic cell transplantation. MD and PhD in Molecular Microbiology and Immunology from Keck School of Medicine (2006) MPhil in History of Medicine from University of Cambridge (2005) Internal Medicine Residency and Hematology Fellowship at Stanford University Dr. Logan's research explores clonotypic diversity in B and T lymphocyte repertoires, utilizing techniques like TREC/KREC quantification, high-throughput sequencing, and mixed lymphocyte reactions. His work has significant applications in tracking immune responses post-transplantation and quantifying measurable residual disease in lymphoid cancers. Notable scientific contributions include advancements in CAR T-cell therapy and immune profiling for blood malignancies. His publications cover topics in B-cell ALL , AML , and measurable residual disease monitoring. 2020 - UCSF Hematology-Oncology Fellowship Teaching Award 2011 - ASH Abstract Award and Research Training Award 2003 - Keck School of Medicine Outstanding Teaching Award As director of the UCSF Hematologic Malignancies Tissue Bank, Dr. Logan provides deidentified patient samples to support collaborative research on blood cancers and post-transplantation immune dynamics.

• Hematology
• Oncology
• Immunology
• +۳ مورد دیگر

Peter A. Jones is President and Chief Scientific Officer at the Van Andel Institute (VAI) in Grand Rapids, Michigan, where he leads the Department of Epigenetics. He previously served as Director of the USC Norris Comprehensive Cancer Center from 1993 to 2011 and has been a central figure in advancing epigenetics research, particularly in cancer. His laboratory investigates DNA methylation, chromatin dynamics, and epigenetic therapies. Research Interests: Dr. Jones's work centers on epigenetic mechanisms in cancer, including DNA methylation, histone modifications, nucleosome positioning, and the therapeutic potential of epigenetic drugs. His research has pioneered the use of DNA methylation inhibitors like 5-azacytidine and explored viral mimicry as a mechanism for immune activation in cancer. He also studies transposable elements and their role in gene regulation and immune response. Publication Trends: His recent publications (2021–2024) reveal a strong focus on the interplay between epigenetics and immunotherapy, particularly how DNA methyltransferase inhibitors (DNMTi) induce viral mimicry, enhance immune recognition, and improve responses to checkpoint blockade. Studies span hematological malignancies, solid tumors, and T cell biology, with frequent collaboration with Stephen Baylin and others. Scientific Awards: Member, National Academy of Sciences Member, National Academy of Medicine Fellow, AACR Academy Fellow, AAAS Fellow, American Academy of Arts and Sciences Kirk A. Landon Award for Basic Cancer Research (2009) Medal of Honor, American Cancer Society (2011) Outstanding Investigator Grant, NCI Harvey Prize (2024) Advising and Grants: Dr. Jones mentors multiple postdoctoral fellows, graduate students, and research scientists. His lab is supported by major grants, including the VAI-SU2C Epigenetics Dream Team, which has launched 15 clinical trials. He has received sustained funding from the National Cancer Institute and collaborates with institutions worldwide to advance epigenetic therapies. Labs and Teams: He leads the Peter Jones Laboratory at VAI, a multidisciplinary team investigating epigenetic regulation in cancer. The lab includes computational biologists, clinical researchers, and molecular biologists, working on both basic mechanisms and translational applications. The team is part of larger collaborative initiatives such as the VAI-SU2C Epigenetics Dream Team and the International Linked Clinical Trials Program.

• Epigenetics
• DNA methylation
• Cancer epigenetics
• +۷ مورد دیگر

Kurt Schalper, MD, PhD is an Associate Professor of Pathology at Yale School of Medicine and Director of the Translational Immuno-Oncology Laboratory (T.I.L.) at Yale Cancer Center. His primary appointment is in the Department of Pathology with secondary appointments in Medical Oncology and Hematology. Dr. Schalper maintains affiliations with multiple cancer research entities including the Cancer Immunology Program, Yale Center for Immuno-Oncology, and the Yale Combined Program in the Biological and Biomedical Sciences (BBS). Dr. Schalper trained as a cell biologist and surgical pathologist, completing his MD at San Sebastian University (2003) and PhD at Universidad Catolica de Chile (2008). His postdoctoral work at Yale focused on developing quantitative strategies to measure immunotherapy-related biomarkers in immune cells and cancer tissues. His research centers on understanding the immunobiology of human solid tumors, particularly lung cancer, with emphasis on immune evasion mechanisms, tumor microenvironment dynamics, and biomarker development for immunotherapy response prediction. Current scientific interests include tumor immune heterogeneity, editing, and the role of specific tumor antigens and immune evasion pathways in lung malignancies. Analysis of Dr. Schalper's recent publications reveals a strong focus on immuno-oncology, particularly in lung cancer. His work spans biomarker development, mechanisms of immunotherapy resistance, tumor microenvironment characterization, and clinical translation of immunotherapeutic approaches. Notable themes include the investigation of KEAP1/STK11-related resistance, IL-4 mediated immune evasion, and strategies to overcome immunotherapy resistance through combination approaches. Dr. Schalper collaborates extensively with Yale researchers, particularly with Dr. David Rimm (57 common publications), Dr. Roy S. Herbst (35 common publications), Dr. Scott Gettinger (14 common publications), and Dr. Sarah Goldberg (12 common publications). His work appears in high-impact journals including Nature, Journal of Clinical Investigation, and Nature Reviews Clinical Oncology. As Director of the Translational Immuno-Oncology Laboratory, Dr. Schalper leads efforts to produce and support high-quality translational research in immuno-oncology through standardized biomarker analyses and integration with Yale resources. His laboratory focuses on developing quantitative methods for immunotherapy biomarker assessment and understanding mechanisms of response and resistance to cancer immunotherapies.

• Immuno-oncology
• Cancer Immunology
• Tumor Microenvironment
• +۳ مورد دیگر

Nikolai Podoltsev, MD, PhD, is an Associate Professor of Medicine (Hematology) at Yale University School of Medicine. He serves as the Associate Director of the Hematology/Oncology Fellowship Program and Clinical Director of Malignant Hematology within the Department of Internal Medicine. Dr. Podoltsev is also the director of the Hematology/Leukemia Tumor Board and represents Yale Cancer Center on National Comprehensive Cancer Network (NCCN) clinical practice guidelines panels, including the Myeloproliferative Neoplasms Panel. Dr. Podoltsev's research focuses on the management of patients with acute leukemias (including acute myeloid leukemias and acute lymphoblastic leukemia), myeloid neoplasms (such as myelodysplastic syndromes and myeloproliferative neoplasms), and bone marrow failure syndromes. His work spans clinical research, epidemiology, and patterns of care for patients with hematological malignancies. As a principal investigator, he leads multiple clinical trials enrolling patients with acute leukemias and myeloid malignancies. Analysis of Dr. Podoltsev's recent publications (2024-2025) reveals a strong focus on therapeutic advancements in myeloid malignancies, particularly acute myeloid leukemia, myelodysplastic syndromes, and myelofibrosis. His research spans drug development (including novel agents like imetelstat and luspatercept), combination therapies, treatment sequencing, and cost-effectiveness analyses. There is a clear emphasis on translating molecular understanding into clinical applications, with significant work on targeted therapies for specific genetic mutations. Yale Cancer Center Award for Clinical Excellence (2022) The David S. Fischer, MD Annual Award for Outstanding Teaching and Mentoring in Hematology (2021, 2017, 2011) As the Associate Director of the Yale Hematology/Oncology Fellowship Program and Yale-New Haven Hospital Duffy Firm Chief for Education, Dr. Podoltsev plays a pivotal role in hematology education for fellows, residents, and medical students. He is actively involved in multiple clinical trials through the Leukemia Clinical Research Team and the Yale Cancer Outcomes Public Policy and Effectiveness Research (COPPER) Center, which enables him to study epidemiology and patterns of care for hematological malignancies. Dr. Podoltsev is part of the Leukemia Disease Aligned Research Team (DART) at Yale Cancer Center, where he contributes to advancing treatment options for patients with blood cancers. His clinical expertise spans the full spectrum of malignant hematology with a particular focus on older adult patients.

• Leukemia
• Myelodysplastic Syndromes
• Myeloproliferative Disorders
• +۴ مورد دیگر

Alexa Siddon, MD, is an Assistant Professor in the Department of Laboratory Medicine at Yale School of Medicine, with secondary appointments in Pathology. She serves as Hematopathology Fellowship Director, Director of the Molecular Diagnostics Laboratory, Director of Flow Cytometry, and Associate Director of the Hematology Laboratory. She is also affiliated with the Yale Cancer Center, Clinical Flow Cytometry Laboratory, and the Hematopathology Laboratory at the Veteran Affairs Connecticut Healthcare System. Dr. Siddon's research focuses on hematopathology, particularly myeloid malignancies, acute leukemias, and post-transplant monitoring. Her work integrates molecular diagnostics, flow cytometry, and genomic analysis to improve patient diagnosis and outcomes. She has co-authored over 10 peer-reviewed articles in recent years, frequently collaborating with leading hematologists and pathologists such as Christopher Tormey, Henry Rinder, and Rory Shallis. Her publications reveal a strong trend in translational research, emphasizing the clinical implications of genetic mutations (e.g., TP53, NPM1, IDH1/2), chimerism testing post-transplant, and immunophenotypic characterization of hematologic malignancies. The research spans disciplines including oncology, molecular biology, immunology, and clinical pathology, with a clear focus on precision diagnostics and prognostic modeling. Scientific Awards: ASCP Distinguished Educator Award Paul J. Strandjord Young Investigator Award Donald H. Buchholz Research Prize Dr. Siddon is actively involved in medical education, directing fellowship programs and mentoring trainees. She has no reported grants listed in the text, but her leadership in diagnostic laboratories and active publication record suggest ongoing research funding. She is not part-time, not retired, and remains a current, active faculty member. She is affiliated with multiple research entities including the Cancer Immunology Center, Center for Biomedical Data Science, and the Yale Cancer Center, contributing to interdisciplinary teams focused on hematologic malignancies and diagnostic innovation.

• Hematopathology
• Molecular Diagnostics
• Flow Cytometry
• +۷ مورد دیگر

Dr. Lingbo Zhang is Assistant Professor in the Department of Pathology & Immunology at Cold Spring Harbor Laboratory, where he directs the Zhang Laboratory and serves as Faculty Head of the Flow Cytometry Shared Resource. He holds a Ph.D. from the joint MIT-NUS program where he trained under Dr. Harvey Lodish. His research focuses on metabolic and neuronal regulation of hematopoietic stem/progenitor cells and hematologic malignancies. Key areas include: Nutrient dependencies in leukemia stem cells Neuronal signaling in hematopoietic regeneration Metabolite-driven oncogenic pathways Vitamin B6 addiction mechanisms in AML Recent publications demonstrate consistent focus on metabolic vulnerabilities in myeloid malignancies and neuronal regulation of erythropoiesis. His team utilizes CRISPR screening, metabolomics, and preclinical models to identify therapeutic targets. Awards include NIH MERIT and EvansMDS Young Investigator Awards recognizing his work on metabolic dependencies in hematologic cancers. He mentors 15+ trainees and leads collaborations with medicinal chemists to develop first-in-class therapeutics targeting metabolic pathways.

• Hematopoietic stem cells
• Tumor microenvironment
• Metabolite regulation
• +۳ مورد دیگر

Haoming Qiu, M.D. serves as an Associate Professor in the Department of Radiation Oncology at the University of Rochester School of Medicine and Dentistry. He practices clinically at both Wilmot Cancer Center in Rochester and Sands Cancer Center in Canandaigua, providing radiation oncology services for gastrointestinal, lung, and prostate cancers. Board-certified by the American Board of Radiology, Dr. Qiu specializes in advanced radiotherapy techniques including external beam radiation and radiopharmaceutical therapies. Education: MD, Johns Hopkins University (2011) Residency in Radiation Oncology, University of Rochester Medical Center (2013-2016) Residency in Radiation Oncology, Loyola University Medical Center (2012-2013) Internship in Internal Medicine, Sinai Hospital of Baltimore (2011-2012) Research Focus: Dr. Qiu's work centers on optimizing radiation therapy for gastrointestinal malignancies, prostate cancer, and neuroendocrine tumors. His investigations into theranostics explore novel applications of Lutathera for neuroendocrine tumors, Pluvicto for prostate cancer, and Therasphere for liver cancers. Current research emphasizes combining stereotactic body radiotherapy with immunotherapeutic agents to overcome treatment resistance in pancreatic and rectal cancers. Publication Trends: Recent publications (2023-2025) reveal a strategic shift toward adaptive radiotherapy techniques for pelvic malignancies and immunoradiotherapy combinations. His work demonstrates growing emphasis on modulating tumor immune microenvironments through radiation, particularly in pancreatic and rectal cancers. The integration of mRNA nanotechnology with SBRT represents a cutting-edge frontier in his research portfolio. Scientific Recognition: Roentgen Resident/Fellow Research Award (2015) Excellence in Medical Student Research (2011) Clinical Leadership: Dr. Qiu directs multiple clinical trials at the University of Rochester focusing on radiopharmaceutical applications and adaptive radiotherapy protocols. His patient-centered approach is reflected in consistently high patient satisfaction scores (4.9/5 stars) across communication, empathy, and treatment explanation metrics. Care Coordination: As part of the Wilmot Cancer Center and Sands Cancer Center teams, Dr. Qiu collaborates with multidisciplinary groups including medical oncologists, surgeons, and radiologists to deliver integrated cancer care through Accountable Health Partners network.

• Radiation Oncology
• Gastrointestinal Cancers
• Lung Cancer
• +۵ مورد دیگر

Brian R. Smith is Professor of Laboratory Medicine, Biomedical Engineering, Internal Medicine (Hematology) and Pediatrics at Yale University. He serves as Deputy Dean for Clinical and Translational Research at the Yale School of Medicine, Co-Director of the Yale Center for Clinical Investigation, and Chair of the Department of Laboratory Medicine. Dr. Smith is also Chief of Laboratory Medicine and Attending Physician at Yale New Haven Hospital, as well as an attending physician at the Connecticut VA Medical Center and Bridgeport Hospital. Dr. Smith's research focuses on the inflammation-hemostasis interface, particularly in relation to biomaterials, and cellular immunotherapeutics. His work spans the full translational spectrum from basic wet bench research through clinical and epidemiological trials (T1-T4). He has been continuously funded by the NIH at the PI-level for over 35 years, demonstrating sustained excellence in translational research. His investigations have particular emphasis on hematologic malignancies, diagnostic accuracy, and the educational frameworks needed to train future laboratory medicine specialists. Analysis of Dr. Smith's publications reveals a consistent focus on advancing laboratory medicine through both clinical research and educational innovation. His work addresses critical issues in diagnostic accuracy, physician-scientist training pathways, and the integration of new technologies into clinical practice. The publications span oncology, hematology, medical education, and healthcare systems, reflecting his interdisciplinary approach to advancing laboratory medicine. Evans Award for Outstanding Contributions to Laboratory Medicine (2010) President, Academy of Clinical Laboratory Physicians & Scientists (2007-2008) Chair (elected), Research Committee and Member of the Council, Association of Pathology Chairs (2010) Dr. Smith has been instrumental in developing Yale's research infrastructure, overseeing implementation of research core facilities in Translational Immune Monitoring, Flow Cytometry, and Clinical Sample Real Time Acquisition. He chairs the Clinical Research Technology Committee and has guided the development of a Cellular Therapy core resource. As an educator, he has personally mentored over 50 MD, MD/PhD, and PhD trainees, most of whom hold tenure-track positions. He is the initiator and long-standing PI of Laboratory Medicine's post-doctoral T32 training program in Immunohematology. Dr. Smith has played a key national role in laboratory medicine education, developing curricula and physician-scientist training paradigms. Through his leadership in the Association of Pathology Chairs, he helped establish a specific Physician-Scientist residency pathway with the American Board of Pathology, addressing a critical need for specialized training in academic pathology.

• inflammation-hemostasis interface
• biomaterials
• cellular immunotherapeutics
• +۷ مورد دیگر

Kathryn E. Dickerson, M.D., M.S.C.S., is an Assistant Professor in the Department of Pediatrics at UT Southwestern Medical Center, specializing in the Division of Hematology and Oncology. She holds dual appointments as a 2015 Translational Research Scholar in the UTSW Center for Translational Medicine and as an NIH KL2 scholar. Her clinical focus is pediatric hematology, emphasizing bone marrow failure disorders, cancer predisposition syndromes, and thalassemia/dyserythropoietic anemias. Her research investigates epigenetic regulation of myeloid malignancies, clonal hematopoiesis in childhood cancer survivors, and molecular mechanisms underlying acute myeloid leukemia (AML), myelodysplastic syndromes (MDS), and myeloproliferative disorders (MPD). Education: Bachelor's in Biochemistry (Indiana University), minor in Spanish Medical degree (Indiana University School of Medicine) Masters of Science in Clinical Sciences (UT Southwestern Center for Translational Medicine) Training: Pediatric residency with research pathway (Ohio State University/Nationwide Children’s Hospital) Pediatric hematology-oncology fellowship (UT Southwestern) Dr. Dickerson’s research bridges basic science and clinical practice, leveraging CRISPR-based epigenetic editing, genomic analysis, and translational studies to understand disease mechanisms. Key projects include interrogating enhancer dysregulation in leukemia, studying metabolic reprogramming in cancers, and evaluating clonal hematopoiesis in survivors of childhood cancers. Her work has advanced understanding of EZH2’s role in AML and identified therapeutic vulnerabilities in myeloid malignancies. Awards: 2015 Translational Research Scholar (UTSW Center for Translational Medicine) NIH KL2 Career Development Award Grants/Initiatives: NIH-funded investigator-initiated study on clonal hematopoiesis Industry/consortia-sponsored trials for bone marrow failure and rare blood disorders She collaborates with the Children’s Research Institute and North American Pediatric Aplastic Anemia Consortium, contributing to clinical trials and translational initiatives. Her lab focuses on developing biomarkers for disease severity (e.g., immature platelet fraction in pediatric COVID-19) and therapeutic strategies targeting epigenetic dependencies in leukemia.

• Pediatric Hematology
• Myeloid Malignancies
• Epigenetic Regulation
• +۴ مورد دیگر

Andrew Godwin is a Professor at the University of Kansas Medical Center , where he serves as the Chancellor’s Distinguished Chair in Biomedical Sciences and Director of Molecular Oncology in the Department of Pathology and Laboratory Medicine. He is also the Deputy Director of the NCI-designated University of Kansas Cancer Center and the Founding Director of the Kansas Institute for Precision Medicine and Biospecimen Shared Resource . Dr. Godwin is a leader in translational research and precision medicine , with a focus on molecular oncology , biomarker discovery , and genomic diagnostics . His work bridges basic and clinical science to improve cancer patient care, particularly in ovarian cancer , Ewing sarcoma , and breast cancer . He has contributed over 230 ovarian cancer-related publications and pioneered studies linking the PI3K/AKT pathway to cancer treatment targets. His research program encompasses liquid biopsies using extracellular vesicles , molecular therapeutics , companion diagnostics , and clinical trial validation . He leads the Biomarker Discovery Laboratory and has secured over $250M in extramural funding , including a $11.4M NIH grant for precision medicine initiatives. His team has developed CELLSEARCH® , the first FDA-cleared test for circulating tumor cells. Notable awards include the Dolph C. Simons, Sr. Higuchi Award (2020), Outstanding Mentorship in Pathology Award (2024), and multiple mentoring accolades from KU. He has mentored over 150 trainees across career stages and leads a multidisciplinary lab with expertise in genomics , proteomics , and bioengineering . Academic Roles: Chancellor’s Distinguished Chair in Biomedical Sciences Director, Molecular Oncology, Pathology and Laboratory Medicine Deputy Director, KU Cancer Center Founding Director, Kansas Institute for Precision Medicine Adjunct Professor, Bioengineering Program, University of Kansas Scientific Awards: KUMC Achievement Award for mentoring postdocs (2014) Chancellor’s Club Award for Research (2018) Dolph C. Simons, Sr. Higuchi Award (2020) KU Excellence in Mentoring Award (2021) Outstanding Mentorship in Pathology (2024) Key Research Themes: Extracellular vesicles as liquid biopsy tools Molecular mechanisms of sarcoma and breast cancer Genomic diagnostics and precision oncology Clinical trial biomarker validation Biospecimen repository leadership

• Molecular Oncology
• Precision Medicine
• Biomarker Discovery
• +۳ مورد دیگر

Howard J. Meyerson is a Professor in the Department of Pathology at Case Western Reserve University's School of Medicine. He serves as a member of the Immune Oncology Program at the Case Comprehensive Cancer Center. His primary roles include Program Director of Hematopathology and Director of Flow Cytometry at University Hospitals Cleveland Medical Center. Research focuses on hematopoietic neoplasms classification, flow cytometric analysis, and immune cell subset evaluation in disorders and therapies. Key collaborations involve high-resolution phenotypic analysis techniques and amplification staining for neoplasm evaluation. Publications emphasize hematologic malignancies, flow cytometry advancements, and immunological mechanisms in blood disorders. Notable works include studies on FLT3-ITD detection in AML, B-ALL diagnostic markers, and clonal cytopenia characterization. Education : MD degree from Case Western Reserve University Professional activities include leadership in clinical pathology training programs and diagnostic laboratory management. Active in collaborative research on immune cell dynamics and therapeutic intervention analysis. Labs/Teams: Leads flow cytometry core facilities and participates in multi-institutional studies on hematologic malignancies.

• Hematopathology
• Flow Cytometry
• Hematopoietic Neoplasms
• +۳ مورد دیگر

Maria R. Baer, MD, is Professor of Medicine and Molecular Medicine at the University of Maryland School of Medicine. She serves as Director of Hematologic Malignancies and Co-Leader of the Experimental Therapeutics Program at the University of Maryland Marlene and Stewart Greenebaum Comprehensive Cancer Center. B.A., Harvard University M.D., Johns Hopkins University School of Medicine Residency and Fellowship, Vanderbilt University Research Focus: Dr. Baer's research centers on drug resistance mechanisms and signal transduction in acute myeloid leukemia (AML) with FLT3 internal tandem duplication (FLT3-ITD). Her work includes preclinical and clinical studies targeting FLT3 and Pim kinases, DNA damage responses, and oxidative stress in AML. Article Trends: Her publications highlight FLT3-ITD as a therapeutic target, explore kinase inhibition strategies, and address chromosomal abnormalities in relapsed AML. Key themes include drug resistance, combination therapies, and molecular pathways like STAT5 and Mcl-1 degradation. Stand Up to Cancer Epigenetics Dream Team Funded by National Cancer Institute, Leukemia and Lymphoma Society, and Department of Veterans Affairs Mentoring: Dr. Baer has a long track record of mentoring students, residents, postdoctoral fellows, and junior faculty in hematologic malignancies research. Labs & Teams: She leads a laboratory at the University of Maryland Greenebaum Cancer Center, collaborating with the CALGB/Alliance for Clinical Trials in Oncology Leukemia Core Committees.

• Leukemia
• Drug Resistance
• Cell Signaling
• +۶ مورد دیگر

Derek S. Tan is a Professor in the Department of Biochemistry and Biophysics at Weill Cornell Medical College, holding a Tri-Institutional Professor position effective from 2025. His research integrates chemical synthesis with biological applications, focusing on drug discovery, enzyme mechanisms, and therapeutic engineering. He maintains an active research program with continuous NIH funding. Education: Ph.D., Harvard University (2000) B.S., Stanford University (1995) Research Focus: Professor Tan's work spans chemical biology, medicinal chemistry, and microbiology. He designs bioactive molecules targeting bacterial permeability, enzyme inhibition, and cellular therapeutics. Key areas include ubiquitin pathway biochemistry, antibiotic development against Mycobacterium tuberculosis and Plasmodium falciparum , and engineered T-cell therapies for cancer. His interdisciplinary approach bridges synthetic chemistry with translational applications. Publication Trends: Recent articles (2021-2024) demonstrate three primary themes: 1) Development of mechanistic probes for enzyme systems (ubiquitin pathway, aminoacyl-tRNA synthetases), 2) Antibacterial/antiparasitic agent design leveraging bacterial permeability studies, and 3) Cellular engineering strategies including CAR-T micropharmacies for targeted drug activation. The work consistently combines synthetic chemistry innovation with biological validation. Grants: As Principal Investigator of the Tri-institutional PhD Program in Chemical Biology (NIH/NIGMS funded), he leads initiatives spanning 2020-2025 and 2025-2030. This underscores sustained commitment to interdisciplinary training at the chemistry-biology interface.

• Chemical Biology
• Medicinal Chemistry
• Biochemistry
• +۳ مورد دیگر